European Medical Journal news story
Kaposi sarcoma responded to chemotherapy in a small prospective study of people living with HIV who maintained long-term viral suppression, although eight participants experienced relapse during follow-up. The findings suggested that treatment remained effective for some patients, but maintaining long-term disease control could prove challenging even when HIV was well controlled.
Kaposi sarcoma is a low-grade vascular tumour caused by Kaposi sarcoma herpesvirus (KSHV/HHV8). In people living with HIV, it is an AIDS-defining cancer that has become less common since the widespread use of combination antiretroviral therapy. However, prospective evidence describing treatment outcomes in patients with sustained HIV virological control has been scarce.
Read the full news story here.
Further coverage on Kaposi sarcoma:
- European Medical Journal: Kaposi Sarcoma risk in people with HIV linked to MAVS gene variant
Source : European Medical Journal
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.